Skip to main content
Top
Published in: Journal of Experimental & Clinical Cancer Research 1/2013

Open Access 01-12-2013 | Research

IL-27 inhibits epithelial-mesenchymal transition and angiogenic factor production in a STAT1-dominant pathway in human non-small cell lung cancer

Authors: Puja Kachroo, Mi-Heon Lee, Ling Zhang, Felicita Baratelli, Gina Lee, Minu K Srivastava, Gerald Wang, Tonya C Walser, Kostyantyn Krysan, Sherven Sharma, Steven M Dubinett, Jay M Lee

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2013

Login to get access

Abstract

Background

Interleukin-27 signaling is mediated by the JAK-STAT pathway via activation of STAT1 and STAT3, which have tumor suppressive and oncogenic activities, respectively. Epithelial–mesenchymal transition (EMT) and angiogenesis are key processes in carcinogenesis. Although IL-27 has been shown to have potent anti-tumor activity in various cancer models, the role of IL-27 in EMT and angiogenesis is poorly understood. In this study, we investigated the role of IL-27 in regulating EMT and angiogenesis through modulation of the STAT pathways in human non-small cell lung carcinoma (NSCLC) cells.

Methods

STAT activation following IL-27 exposure was measured in human NSCLC cell lines. Expression of epithelial (E-cadherin, γ-catenin) and mesenchymal (N-cadherin, vimentin) markers were assessed by Western blot analysis. Production of pro-angiogenic factors (VEGF, IL-8/CXCL8, CXCL5) were examined by ELISA. Cell motility was examined by an in vitro scratch and transwell migration assays. Selective inhibitors of STAT1 (STAT1 siRNAs) and STAT3 (Stattic) were used to determine whether both STAT1 and STAT3 are required for IL-27 mediated inhibition of EMT and secretion of angiogenic factors.

Results

Our results demonstrate that IL-27 stimulation in NSCLC resulted in 1) STAT1 and STAT3 activation in a JAK-dependent manner, 2) development of epithelial phenotypes, including a decrease in the expression of a transcriptional repressor for E-cadherin (SNAIL), and mesenchymal marker (vimentin) with a reciprocal increase in the expression of epithelial markers, 3) inhibition of cell migration, and 4) reduced production of pro-angiogenic factors. STAT1 inhibition in IL-27–treated cells reversed the IL-27 effect with resultant increased expression of Snail, vimentin and the pro-angiogenic factors. The inhibition of STAT3 activation had no effect on the development of the epithelial phenotype.

Conclusion

IL-27 induces mesenchymal to epithelial transition and inhibits the production of pro-angiogenic factors in a STAT1–dominant pathway. These findings highlight the importance of STAT1 in repressing lung carcinogenesis and describe a new anti-tumor mechanism of IL-27.
Appendix
Available only for authorised users
Literature
1.
go back to reference Villarino AV, Huang E, Hunter CA: Understanding the pro- and anti-inflammatory properties of IL-27. J Immunol. 2004, 173 (2): 715-720.CrossRef Villarino AV, Huang E, Hunter CA: Understanding the pro- and anti-inflammatory properties of IL-27. J Immunol. 2004, 173 (2): 715-720.CrossRef
2.
go back to reference Salcedo R, Stauffer JK, Lincoln E, Back TC, Hixon JA, Hahn C, Shafer-Weaver K, Malyguine A, Kastelein R, Wigginton JM: IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8+ T cells. J Immunol. 2004, 173 (12): 7170-7182.CrossRef Salcedo R, Stauffer JK, Lincoln E, Back TC, Hixon JA, Hahn C, Shafer-Weaver K, Malyguine A, Kastelein R, Wigginton JM: IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8+ T cells. J Immunol. 2004, 173 (12): 7170-7182.CrossRef
3.
go back to reference Cocco C, Giuliani N, Di Carlo E, Ognio E, Storti P, Abeltino M, Sorrentino C, Ponzoni M, Ribatti D, Airoldi I: Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma. Clin Cancer Res. 2010, 16 (16): 4188-4197. 10.1158/1078-0432.CCR-10-0173.CrossRef Cocco C, Giuliani N, Di Carlo E, Ognio E, Storti P, Abeltino M, Sorrentino C, Ponzoni M, Ribatti D, Airoldi I: Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma. Clin Cancer Res. 2010, 16 (16): 4188-4197. 10.1158/1078-0432.CCR-10-0173.CrossRef
4.
go back to reference Chiyo M, Shimozato O, Yu L, Kawamura K, Iizasa T, Fujisawa T, Tagawa M: Expression of IL-27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals. Int J Cancer. 2005, 115 (3): 437-442. 10.1002/ijc.20848.CrossRef Chiyo M, Shimozato O, Yu L, Kawamura K, Iizasa T, Fujisawa T, Tagawa M: Expression of IL-27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals. Int J Cancer. 2005, 115 (3): 437-442. 10.1002/ijc.20848.CrossRef
5.
go back to reference Shimizu M, Shimamura M, Owaki T, Asakawa M, Fujita K, Kudo M, Iwakura Y, Takeda Y, Luster AD, Mizuguchi J, et al: Antiangiogenic and antitumor activities of IL-27. J Immunol. 2006, 176 (12): 7317-7324.CrossRef Shimizu M, Shimamura M, Owaki T, Asakawa M, Fujita K, Kudo M, Iwakura Y, Takeda Y, Luster AD, Mizuguchi J, et al: Antiangiogenic and antitumor activities of IL-27. J Immunol. 2006, 176 (12): 7317-7324.CrossRef
6.
go back to reference Hisada M, Kamiya S, Fujita K, Belladonna ML, Aoki T, Koyanagi Y, Mizuguchi J, Yoshimoto T: Potent antitumor activity of interleukin-27. Cancer Res. 2004, 64 (3): 1152-1156. 10.1158/0008-5472.CAN-03-2084.CrossRef Hisada M, Kamiya S, Fujita K, Belladonna ML, Aoki T, Koyanagi Y, Mizuguchi J, Yoshimoto T: Potent antitumor activity of interleukin-27. Cancer Res. 2004, 64 (3): 1152-1156. 10.1158/0008-5472.CAN-03-2084.CrossRef
7.
go back to reference Oniki S, Nagai H, Horikawa T, Furukawa J, Belladonna ML, Yoshimoto T, Hara I, Nishigori C: Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma. Cancer Res. 2006, 66 (12): 6395-6404. 10.1158/0008-5472.CAN-05-4087.CrossRef Oniki S, Nagai H, Horikawa T, Furukawa J, Belladonna ML, Yoshimoto T, Hara I, Nishigori C: Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma. Cancer Res. 2006, 66 (12): 6395-6404. 10.1158/0008-5472.CAN-05-4087.CrossRef
8.
go back to reference Yoshimoto T, Morishima N, Mizoguchi I, Shimizu M, Nagai H, Oniki S, Oka M, Nishigori C, Mizuguchi J: Antiproliferative activity of IL-27 on melanoma. J Immunol. 2008, 180 (10): 6527-6535.CrossRef Yoshimoto T, Morishima N, Mizoguchi I, Shimizu M, Nagai H, Oniki S, Oka M, Nishigori C, Mizuguchi J: Antiproliferative activity of IL-27 on melanoma. J Immunol. 2008, 180 (10): 6527-6535.CrossRef
9.
go back to reference Hurteau JA, Blessing JA, DeCesare SL, Creasman WT: Evaluation of recombinant human interleukin-12 in patients with recurrent or refractory ovarian cancer: a gynecologic oncology group study. Gynecol Oncol. 2001, 82 (1): 7-10.CrossRef Hurteau JA, Blessing JA, DeCesare SL, Creasman WT: Evaluation of recombinant human interleukin-12 in patients with recurrent or refractory ovarian cancer: a gynecologic oncology group study. Gynecol Oncol. 2001, 82 (1): 7-10.CrossRef
10.
go back to reference Motzer RJ, Rakhit A, Thompson JA, Nemunaitis J, Murphy BA, Ellerhorst J, Schwartz LH, Berg WJ, Bukowski RM: Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma. J Interferon Cytokine Res. 2001, 21 (4): 257-263. 10.1089/107999001750169934.CrossRef Motzer RJ, Rakhit A, Thompson JA, Nemunaitis J, Murphy BA, Ellerhorst J, Schwartz LH, Berg WJ, Bukowski RM: Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma. J Interferon Cytokine Res. 2001, 21 (4): 257-263. 10.1089/107999001750169934.CrossRef
11.
go back to reference Darnell JE: STATs and gene regulation. Science. 1997, 277 (5332): 1630-1635. 10.1126/science.277.5332.1630.CrossRef Darnell JE: STATs and gene regulation. Science. 1997, 277 (5332): 1630-1635. 10.1126/science.277.5332.1630.CrossRef
12.
go back to reference Stephanou A, Latchman DS: STAT-1: a novel regulator of apoptosis. Int J Exp Pathol. 2003, 84 (6): 239-244.CrossRef Stephanou A, Latchman DS: STAT-1: a novel regulator of apoptosis. Int J Exp Pathol. 2003, 84 (6): 239-244.CrossRef
13.
go back to reference Huang M, Page C, Reynolds RK, Lin J: Constitutive activation of stat 3 oncogene product in human ovarian carcinoma cells. Gynecol Oncol. 2000, 79 (1): 67-73. 10.1006/gyno.2000.5931.CrossRef Huang M, Page C, Reynolds RK, Lin J: Constitutive activation of stat 3 oncogene product in human ovarian carcinoma cells. Gynecol Oncol. 2000, 79 (1): 67-73. 10.1006/gyno.2000.5931.CrossRef
14.
go back to reference Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell JE: Stat3 as an oncogene. Cell. 1999, 98 (3): 295-303. 10.1016/S0092-8674(00)81959-5.CrossRef Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell JE: Stat3 as an oncogene. Cell. 1999, 98 (3): 295-303. 10.1016/S0092-8674(00)81959-5.CrossRef
15.
go back to reference Levy DE, Inghirami G: STAT3: a multifaceted oncogene. Proc Natl Acad Sci USA. 2006, 103 (27): 10151-10152. 10.1073/pnas.0604042103.CrossRef Levy DE, Inghirami G: STAT3: a multifaceted oncogene. Proc Natl Acad Sci USA. 2006, 103 (27): 10151-10152. 10.1073/pnas.0604042103.CrossRef
16.
go back to reference Huang S, Bucana CD, Van Arsdall M, Fidler IJ: Stat1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells. Oncogene. 2002, 21 (16): 2504-2512. 10.1038/sj.onc.1205341.CrossRef Huang S, Bucana CD, Van Arsdall M, Fidler IJ: Stat1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells. Oncogene. 2002, 21 (16): 2504-2512. 10.1038/sj.onc.1205341.CrossRef
17.
go back to reference Deng JY, Sun D, Liu XY, Pan Y, Liang H: STAT-3 correlates with lymph node metastasis and cell survival in gastric cancer. World J Gastroenterol. 2010, 16 (42): 5380-5387. 10.3748/wjg.v16.i42.5380.CrossRef Deng JY, Sun D, Liu XY, Pan Y, Liang H: STAT-3 correlates with lymph node metastasis and cell survival in gastric cancer. World J Gastroenterol. 2010, 16 (42): 5380-5387. 10.3748/wjg.v16.i42.5380.CrossRef
18.
go back to reference Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, et al: Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene. 2002, 21 (13): 2000-2008. 10.1038/sj.onc.1205260.CrossRef Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, et al: Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene. 2002, 21 (13): 2000-2008. 10.1038/sj.onc.1205260.CrossRef
19.
go back to reference Horiguchi A, Oya M, Shimada T, Uchida A, Marumo K, Murai M: Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of incidence and its association with pathological features and clinical outcome. J Urol. 2002, 168 (2): 762-765. 10.1016/S0022-5347(05)64741-6.CrossRef Horiguchi A, Oya M, Shimada T, Uchida A, Marumo K, Murai M: Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of incidence and its association with pathological features and clinical outcome. J Urol. 2002, 168 (2): 762-765. 10.1016/S0022-5347(05)64741-6.CrossRef
20.
go back to reference Chang KC, Wu MH, Jones D, Chen FF, Tseng YL: Activation of STAT3 in thymic epithelial tumours correlates with tumour type and clinical behaviour. J Pathol. 2006, 210 (2): 224-233. 10.1002/path.2041.CrossRef Chang KC, Wu MH, Jones D, Chen FF, Tseng YL: Activation of STAT3 in thymic epithelial tumours correlates with tumour type and clinical behaviour. J Pathol. 2006, 210 (2): 224-233. 10.1002/path.2041.CrossRef
21.
go back to reference David D, Rajappan LM, Balachandran K, Thulaseedharan JV, Nair AS, Pillai RM: Prognostic significance of STAT3 and phosphorylated STAT3 in human soft tissue tumors - a clinicopathological analysis. J Exp Clin Cancer Res. 2011, 30: 56-10.1186/1756-9966-30-56.CrossRef David D, Rajappan LM, Balachandran K, Thulaseedharan JV, Nair AS, Pillai RM: Prognostic significance of STAT3 and phosphorylated STAT3 in human soft tissue tumors - a clinicopathological analysis. J Exp Clin Cancer Res. 2011, 30: 56-10.1186/1756-9966-30-56.CrossRef
22.
go back to reference Hunter CA: New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol. 2005, 5 (7): 521-531. 10.1038/nri1648.CrossRef Hunter CA: New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol. 2005, 5 (7): 521-531. 10.1038/nri1648.CrossRef
23.
go back to reference Leonard WJ, O'Shea JJ: Jaks and STATs: biological implications. Annu Rev Immunol. 1998, 16: 293-322. 10.1146/annurev.immunol.16.1.293.CrossRef Leonard WJ, O'Shea JJ: Jaks and STATs: biological implications. Annu Rev Immunol. 1998, 16: 293-322. 10.1146/annurev.immunol.16.1.293.CrossRef
24.
go back to reference Hay ED: The mesenchymal cell, its role in the embryo, and the remarkable signaling mechanisms that create it. Dev Dyn. 2005, 233 (3): 706-720. 10.1002/dvdy.20345.CrossRef Hay ED: The mesenchymal cell, its role in the embryo, and the remarkable signaling mechanisms that create it. Dev Dyn. 2005, 233 (3): 706-720. 10.1002/dvdy.20345.CrossRef
25.
go back to reference Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED, Thompson EW: Epithelial–mesenchymal and mesenchymal–epithelial transitions in carcinoma progression. J Cell Physiol. 2007, 213 (2): 374-383. 10.1002/jcp.21223.CrossRef Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED, Thompson EW: Epithelial–mesenchymal and mesenchymal–epithelial transitions in carcinoma progression. J Cell Physiol. 2007, 213 (2): 374-383. 10.1002/jcp.21223.CrossRef
26.
go back to reference Lee TK, Poon RT, Yuen AP, Ling MT, Kwok WK, Wang XH, Wong YC, Guan XY, Man K, Chau KL, et al: Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin Cancer Res. 2006, 12 (18): 5369-5376. 10.1158/1078-0432.CCR-05-2722.CrossRef Lee TK, Poon RT, Yuen AP, Ling MT, Kwok WK, Wang XH, Wong YC, Guan XY, Man K, Chau KL, et al: Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin Cancer Res. 2006, 12 (18): 5369-5376. 10.1158/1078-0432.CCR-05-2722.CrossRef
27.
go back to reference Ho MY, Leu SJ, Sun GH, Tao MH, Tang SJ, Sun KH: IL-27 directly restrains lung tumorigenicity by suppressing cyclooxygenase-2-mediated activities. J Immunol. 2009, 183 (10): 6217-6226. 10.4049/jimmunol.0901272.CrossRef Ho MY, Leu SJ, Sun GH, Tao MH, Tang SJ, Sun KH: IL-27 directly restrains lung tumorigenicity by suppressing cyclooxygenase-2-mediated activities. J Immunol. 2009, 183 (10): 6217-6226. 10.4049/jimmunol.0901272.CrossRef
28.
go back to reference Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA, et al: Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013, 499 (7457): 214-218. 10.1038/nature12213.CrossRef Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA, et al: Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013, 499 (7457): 214-218. 10.1038/nature12213.CrossRef
29.
go back to reference Reddy EP, Korapati A, Chaturvedi P, Rane S: IL-3 signaling and the role of Src kinases, JAKs and STATs: a covert liaison unveiled. Oncogene. 2000, 19 (21): 2532-2547. 10.1038/sj.onc.1203594.CrossRef Reddy EP, Korapati A, Chaturvedi P, Rane S: IL-3 signaling and the role of Src kinases, JAKs and STATs: a covert liaison unveiled. Oncogene. 2000, 19 (21): 2532-2547. 10.1038/sj.onc.1203594.CrossRef
30.
go back to reference Ernst M, Jenkins BJ: Acquiring signalling specificity from the cytokine receptor gp130. Trends Genet. 2004, 20 (1): 23-32. 10.1016/j.tig.2003.11.003.CrossRef Ernst M, Jenkins BJ: Acquiring signalling specificity from the cytokine receptor gp130. Trends Genet. 2004, 20 (1): 23-32. 10.1016/j.tig.2003.11.003.CrossRef
31.
go back to reference Fiszer-Kierzkowska A, Vydra N, Wysocka-Wycisk A, Kronekova Z, Jarzab M, Lisowska KM, Krawczyk Z: Liposome-based DNA carriers may induce cellular stress response and change gene expression pattern in transfected cells. BMC Mol Biol. 2011, 12: 27-10.1186/1471-2199-12-27.CrossRef Fiszer-Kierzkowska A, Vydra N, Wysocka-Wycisk A, Kronekova Z, Jarzab M, Lisowska KM, Krawczyk Z: Liposome-based DNA carriers may induce cellular stress response and change gene expression pattern in transfected cells. BMC Mol Biol. 2011, 12: 27-10.1186/1471-2199-12-27.CrossRef
32.
go back to reference Song L, Turkson J, Karras JG, Jove R, Haura EB: Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene. 2003, 22 (27): 4150-4165. 10.1038/sj.onc.1206479.CrossRef Song L, Turkson J, Karras JG, Jove R, Haura EB: Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene. 2003, 22 (27): 4150-4165. 10.1038/sj.onc.1206479.CrossRef
33.
go back to reference Schust J, Sperl B, Hollis A, Mayer TU, Berg T: Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol. 2006, 13 (11): 1235-1242. 10.1016/j.chembiol.2006.09.018.CrossRef Schust J, Sperl B, Hollis A, Mayer TU, Berg T: Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol. 2006, 13 (11): 1235-1242. 10.1016/j.chembiol.2006.09.018.CrossRef
34.
go back to reference Kalluri R, Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest. 2009, 119 (6): 1420-1428. 10.1172/JCI39104.CrossRef Kalluri R, Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest. 2009, 119 (6): 1420-1428. 10.1172/JCI39104.CrossRef
35.
go back to reference Strutz F, Zeisberg M, Ziyadeh FN, Yang CQ, Kalluri R, Muller GA, Neilson EG: Role of basic fibroblast growth factor-2 in epithelial-mesenchymal transformation. Kidney Int. 2002, 61 (5): 1714-1728. 10.1046/j.1523-1755.2002.00333.x.CrossRef Strutz F, Zeisberg M, Ziyadeh FN, Yang CQ, Kalluri R, Muller GA, Neilson EG: Role of basic fibroblast growth factor-2 in epithelial-mesenchymal transformation. Kidney Int. 2002, 61 (5): 1714-1728. 10.1046/j.1523-1755.2002.00333.x.CrossRef
36.
go back to reference Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, Portillo F, Nieto MA: The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol. 2000, 2 (2): 76-83. 10.1038/35000025.CrossRef Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, Portillo F, Nieto MA: The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol. 2000, 2 (2): 76-83. 10.1038/35000025.CrossRef
37.
go back to reference Vernon AE, LaBonne C: Tumor metastasis: a new twist on epithelial-mesenchymal transitions. Curr Biol. 2004, 14 (17): R719-R721. 10.1016/j.cub.2004.08.048.CrossRef Vernon AE, LaBonne C: Tumor metastasis: a new twist on epithelial-mesenchymal transitions. Curr Biol. 2004, 14 (17): R719-R721. 10.1016/j.cub.2004.08.048.CrossRef
38.
go back to reference Thiery JP: Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol. 2003, 15 (6): 740-746. 10.1016/j.ceb.2003.10.006.CrossRef Thiery JP: Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol. 2003, 15 (6): 740-746. 10.1016/j.ceb.2003.10.006.CrossRef
39.
go back to reference Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature. 2000, 407 (6801): 249-257. 10.1038/35025220.CrossRef Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature. 2000, 407 (6801): 249-257. 10.1038/35025220.CrossRef
40.
go back to reference Folkman J: Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 2002, 29 (6 Suppl 16): 15-18.CrossRef Folkman J: Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 2002, 29 (6 Suppl 16): 15-18.CrossRef
41.
go back to reference Tonini T, Rossi F, Claudio PP: Molecular basis of angiogenesis and cancer. Oncogene. 2003, 22 (42): 6549-6556. 10.1038/sj.onc.1206816.CrossRef Tonini T, Rossi F, Claudio PP: Molecular basis of angiogenesis and cancer. Oncogene. 2003, 22 (42): 6549-6556. 10.1038/sj.onc.1206816.CrossRef
42.
go back to reference Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J: Vascular-specific growth factors and blood vessel formation. Nature. 2000, 407 (6801): 242-248. 10.1038/35025215.CrossRef Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J: Vascular-specific growth factors and blood vessel formation. Nature. 2000, 407 (6801): 242-248. 10.1038/35025215.CrossRef
43.
go back to reference Arenberg DA, Kunkel SL, Polverini PJ, Glass M, Burdick MD, Strieter RM: Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J Clin Invest. 1996, 97 (12): 2792-2802. 10.1172/JCI118734.CrossRef Arenberg DA, Kunkel SL, Polverini PJ, Glass M, Burdick MD, Strieter RM: Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J Clin Invest. 1996, 97 (12): 2792-2802. 10.1172/JCI118734.CrossRef
44.
go back to reference Arenberg DA, Keane MP, DiGiovine B, Kunkel SL, Morris SB, Xue YY, Burdick MD, Glass MC, Iannettoni MD, Strieter RM: Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer. J Clin Invest. 1998, 102 (3): 465-472. 10.1172/JCI3145.CrossRef Arenberg DA, Keane MP, DiGiovine B, Kunkel SL, Morris SB, Xue YY, Burdick MD, Glass MC, Iannettoni MD, Strieter RM: Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer. J Clin Invest. 1998, 102 (3): 465-472. 10.1172/JCI3145.CrossRef
45.
go back to reference Battle TE, Lynch RA, Frank DA: Signal transducer and activator of transcription 1 activation in endothelial cells is a negative regulator of angiogenesis. Cancer Res. 2006, 66 (7): 3649-3657. 10.1158/0008-5472.CAN-05-3612.CrossRef Battle TE, Lynch RA, Frank DA: Signal transducer and activator of transcription 1 activation in endothelial cells is a negative regulator of angiogenesis. Cancer Res. 2006, 66 (7): 3649-3657. 10.1158/0008-5472.CAN-05-3612.CrossRef
46.
go back to reference von Marschall Z, Scholz A, Cramer T, Schafer G, Schirner M, Oberg K, Wiedenmann B, Hocker M, Rosewicz S: Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst. 2003, 95 (6): 437-448. 10.1093/jnci/95.6.437.CrossRef von Marschall Z, Scholz A, Cramer T, Schafer G, Schirner M, Oberg K, Wiedenmann B, Hocker M, Rosewicz S: Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst. 2003, 95 (6): 437-448. 10.1093/jnci/95.6.437.CrossRef
47.
go back to reference Gray MJ, Zhang J, Ellis LM, Semenza GL, Evans DB, Watowich SS, Gallick GE: HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene. 2005, 24 (19): 3110-3120. 10.1038/sj.onc.1208513.CrossRef Gray MJ, Zhang J, Ellis LM, Semenza GL, Evans DB, Watowich SS, Gallick GE: HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene. 2005, 24 (19): 3110-3120. 10.1038/sj.onc.1208513.CrossRef
48.
go back to reference Laver T, Nozell SE, Benveniste EN: IFN-beta-mediated inhibition of IL-8 expression requires the ISGF3 components Stat1, Stat2, and IRF-9. J Interferon Cytokine Res. 2008, 28 (1): 13-23. 10.1089/jir.2007.0062.CrossRef Laver T, Nozell SE, Benveniste EN: IFN-beta-mediated inhibition of IL-8 expression requires the ISGF3 components Stat1, Stat2, and IRF-9. J Interferon Cytokine Res. 2008, 28 (1): 13-23. 10.1089/jir.2007.0062.CrossRef
49.
go back to reference Oka M, Sakaguchi M, Okada T, Nagai H, Ozaki M, Yoshioka T, Inoue H, Mukaida N, Kikkawa U, Nishigori C: Signal transducer and activator of transcription 3 upregulates interleukin-8 expression at the level of transcription in human melanoma cells. Exp Dermatol. 2010, 19 (8): e50-e55.CrossRef Oka M, Sakaguchi M, Okada T, Nagai H, Ozaki M, Yoshioka T, Inoue H, Mukaida N, Kikkawa U, Nishigori C: Signal transducer and activator of transcription 3 upregulates interleukin-8 expression at the level of transcription in human melanoma cells. Exp Dermatol. 2010, 19 (8): e50-e55.CrossRef
50.
go back to reference Sanchez-Garcia I: The crossroads of oncogenesis and metastasis. N Engl J Med. 2009, 360 (3): 297-299. 10.1056/NEJMcibr0808031.CrossRef Sanchez-Garcia I: The crossroads of oncogenesis and metastasis. N Engl J Med. 2009, 360 (3): 297-299. 10.1056/NEJMcibr0808031.CrossRef
51.
go back to reference Dohadwala M, Yang SC, Luo J, Sharma S, Batra RK, Huang M, Lin Y, Goodglick L, Krysan K, Fishbein MC, et al: Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer. Cancer Res. 2006, 66 (10): 5338-5345. 10.1158/0008-5472.CAN-05-3635.CrossRef Dohadwala M, Yang SC, Luo J, Sharma S, Batra RK, Huang M, Lin Y, Goodglick L, Krysan K, Fishbein MC, et al: Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer. Cancer Res. 2006, 66 (10): 5338-5345. 10.1158/0008-5472.CAN-05-3635.CrossRef
52.
go back to reference Liu X, Robinson GW, Wagner KU, Garrett L, Wynshaw-Boris A, Hennighausen L: Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev. 1997, 11 (2): 179-186. 10.1101/gad.11.2.179.CrossRef Liu X, Robinson GW, Wagner KU, Garrett L, Wynshaw-Boris A, Hennighausen L: Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev. 1997, 11 (2): 179-186. 10.1101/gad.11.2.179.CrossRef
53.
go back to reference Kim M, O'Brien LE, Kwon SH, Mostov KE: STAT1 is required for redifferentiation during Madin-Darby canine kidney tubulogenesis. Mol Biol Cell. 2010, 21 (22): 3926-3933. 10.1091/mbc.E10-02-0112.CrossRef Kim M, O'Brien LE, Kwon SH, Mostov KE: STAT1 is required for redifferentiation during Madin-Darby canine kidney tubulogenesis. Mol Biol Cell. 2010, 21 (22): 3926-3933. 10.1091/mbc.E10-02-0112.CrossRef
54.
go back to reference Sato M, Shames DS, Hasegawa Y: Emerging evidence of epithelial-to-mesenchymal transition in lung carcinogenesis. Respirology. 2012, 17 (7): 1048-1059. 10.1111/j.1440-1843.2012.02173.x.CrossRef Sato M, Shames DS, Hasegawa Y: Emerging evidence of epithelial-to-mesenchymal transition in lung carcinogenesis. Respirology. 2012, 17 (7): 1048-1059. 10.1111/j.1440-1843.2012.02173.x.CrossRef
55.
go back to reference Kase S, Sugio K, Yamazaki K, Okamoto T, Yano T, Sugimachi K: Expression of E-cadherin and beta-catenin in human non-small cell lung cancer and the clinical significance. Clin Cancer Res. 2000, 6 (12): 4789-4796. Kase S, Sugio K, Yamazaki K, Okamoto T, Yano T, Sugimachi K: Expression of E-cadherin and beta-catenin in human non-small cell lung cancer and the clinical significance. Clin Cancer Res. 2000, 6 (12): 4789-4796.
56.
go back to reference Pirinen RT, Hirvikoski P, Johansson RT, Hollmen S, Kosma VM: Reduced expression of alpha-catenin, beta-catenin, and gamma-catenin is associated with high cell proliferative activity and poor differentiation in non-small cell lung cancer. J Clin Pathol. 2001, 54 (5): 391-395. 10.1136/jcp.54.5.391.CrossRef Pirinen RT, Hirvikoski P, Johansson RT, Hollmen S, Kosma VM: Reduced expression of alpha-catenin, beta-catenin, and gamma-catenin is associated with high cell proliferative activity and poor differentiation in non-small cell lung cancer. J Clin Pathol. 2001, 54 (5): 391-395. 10.1136/jcp.54.5.391.CrossRef
57.
go back to reference Iwatsuki M, Mimori K, Yokobori T, Ishi H, Beppu T, Nakamori S, Baba H, Mori M: Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci. 2010, 101 (2): 293-299. 10.1111/j.1349-7006.2009.01419.x.CrossRef Iwatsuki M, Mimori K, Yokobori T, Ishi H, Beppu T, Nakamori S, Baba H, Mori M: Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci. 2010, 101 (2): 293-299. 10.1111/j.1349-7006.2009.01419.x.CrossRef
58.
go back to reference Satelli A, Li S: Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci. 2011, 68 (18): 3033-3046. 10.1007/s00018-011-0735-1.CrossRef Satelli A, Li S: Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci. 2011, 68 (18): 3033-3046. 10.1007/s00018-011-0735-1.CrossRef
59.
go back to reference Gil MP, Bohn E, O'Guin AK, Ramana CV, Levine B, Stark GR, Virgin HW, Schreiber RD: Biologic consequences of Stat1-independent IFN signaling. Proc Natl Acad Sci USA. 2001, 98 (12): 6680-6685. 10.1073/pnas.111163898.CrossRef Gil MP, Bohn E, O'Guin AK, Ramana CV, Levine B, Stark GR, Virgin HW, Schreiber RD: Biologic consequences of Stat1-independent IFN signaling. Proc Natl Acad Sci USA. 2001, 98 (12): 6680-6685. 10.1073/pnas.111163898.CrossRef
60.
go back to reference Qing Y, Stark GR: Alternative activation of STAT1 and STAT3 in response to interferon-gamma. J Biol Chem. 2004, 279 (40): 41679-41685. 10.1074/jbc.M406413200.CrossRef Qing Y, Stark GR: Alternative activation of STAT1 and STAT3 in response to interferon-gamma. J Biol Chem. 2004, 279 (40): 41679-41685. 10.1074/jbc.M406413200.CrossRef
61.
go back to reference Ramana CV, Gil MP, Han Y, Ransohoff RM, Schreiber RD, Stark GR: Stat1-independent regulation of gene expression in response to IFN-gamma. Proc Natl Acad Sci USA. 2001, 98 (12): 6674-6679. 10.1073/pnas.111164198.CrossRef Ramana CV, Gil MP, Han Y, Ransohoff RM, Schreiber RD, Stark GR: Stat1-independent regulation of gene expression in response to IFN-gamma. Proc Natl Acad Sci USA. 2001, 98 (12): 6674-6679. 10.1073/pnas.111164198.CrossRef
62.
go back to reference Kerr IM, Costa-Pereira AP, Lillemeier BF, Strobl B: Of JAKs, STATs, blind watchmakers, jeeps and trains. FEBS Lett. 2003, 546 (1): 1-5. 10.1016/S0014-5793(03)00411-3.CrossRef Kerr IM, Costa-Pereira AP, Lillemeier BF, Strobl B: Of JAKs, STATs, blind watchmakers, jeeps and trains. FEBS Lett. 2003, 546 (1): 1-5. 10.1016/S0014-5793(03)00411-3.CrossRef
63.
go back to reference Ihle JN, Kerr IM: Jaks and Stats in signaling by the cytokine receptor superfamily. Trends Genet. 1995, 11 (2): 69-74. 10.1016/S0168-9525(00)89000-9.CrossRef Ihle JN, Kerr IM: Jaks and Stats in signaling by the cytokine receptor superfamily. Trends Genet. 1995, 11 (2): 69-74. 10.1016/S0168-9525(00)89000-9.CrossRef
64.
go back to reference Sano S, Itami S, Takeda K, Tarutani M, Yamaguchi Y, Miura H, Yoshikawa K, Akira S, Takeda J: Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO J. 1999, 18 (17): 4657-4668. 10.1093/emboj/18.17.4657.CrossRef Sano S, Itami S, Takeda K, Tarutani M, Yamaguchi Y, Miura H, Yoshikawa K, Akira S, Takeda J: Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO J. 1999, 18 (17): 4657-4668. 10.1093/emboj/18.17.4657.CrossRef
65.
go back to reference Lim CP, Phan TT, Lim IJ, Cao X: Stat3 contributes to keloid pathogenesis via promoting collagen production, cell proliferation and migration. Oncogene. 2006, 25 (39): 5416-5425. 10.1038/sj.onc.1209531.CrossRef Lim CP, Phan TT, Lim IJ, Cao X: Stat3 contributes to keloid pathogenesis via promoting collagen production, cell proliferation and migration. Oncogene. 2006, 25 (39): 5416-5425. 10.1038/sj.onc.1209531.CrossRef
66.
go back to reference Ng DC, Lin BH, Lim CP, Huang G, Zhang T, Poli V, Cao X: Stat3 regulates microtubules by antagonizing the depolymerization activity of stathmin. J Cell Biol. 2006, 172 (2): 245-257. 10.1083/jcb.200503021.CrossRef Ng DC, Lin BH, Lim CP, Huang G, Zhang T, Poli V, Cao X: Stat3 regulates microtubules by antagonizing the depolymerization activity of stathmin. J Cell Biol. 2006, 172 (2): 245-257. 10.1083/jcb.200503021.CrossRef
67.
go back to reference Bhinge AA, Kim J, Euskirchen GM, Snyder M, Iyer VR: Mapping the chromosomal targets of STAT1 by Sequence Tag Analysis of Genomic Enrichment (STAGE). Genome Res. 2007, 17 (6): 910-916. 10.1101/gr.5574907.CrossRef Bhinge AA, Kim J, Euskirchen GM, Snyder M, Iyer VR: Mapping the chromosomal targets of STAT1 by Sequence Tag Analysis of Genomic Enrichment (STAGE). Genome Res. 2007, 17 (6): 910-916. 10.1101/gr.5574907.CrossRef
68.
go back to reference Ramana CV, Kumar A, Enelow R: Stat1-independent induction of SOCS-3 by interferon-gamma is mediated by sustained activation of Stat3 in mouse embryonic fibroblasts. Biochem Biophys Res Commun. 2005, 327 (3): 727-733. 10.1016/j.bbrc.2004.12.074.CrossRef Ramana CV, Kumar A, Enelow R: Stat1-independent induction of SOCS-3 by interferon-gamma is mediated by sustained activation of Stat3 in mouse embryonic fibroblasts. Biochem Biophys Res Commun. 2005, 327 (3): 727-733. 10.1016/j.bbrc.2004.12.074.CrossRef
Metadata
Title
IL-27 inhibits epithelial-mesenchymal transition and angiogenic factor production in a STAT1-dominant pathway in human non-small cell lung cancer
Authors
Puja Kachroo
Mi-Heon Lee
Ling Zhang
Felicita Baratelli
Gina Lee
Minu K Srivastava
Gerald Wang
Tonya C Walser
Kostyantyn Krysan
Sherven Sharma
Steven M Dubinett
Jay M Lee
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2013
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/1756-9966-32-97

Other articles of this Issue 1/2013

Journal of Experimental & Clinical Cancer Research 1/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine